

Please try another search
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive and monotherapy treatment of major depressive disorder.
Name | Age | Since | Title |
---|---|---|---|
Sergio Traversa | 61 | 2012 | CEO & Director |
Charles J. Casamento | 76 | 2015 | Independent Chairman of the Board |
Maged S. Shenouda | 57 | 2020 | Chief Financial Officer |
Maurizio Fava | - | 2017 | Member of Scientific Advisory Board |
Charles E. Inturrisi | - | - | Member of Scientific Advisory Board |
Dan Iosifescu | - | 2020 | Member of Scientific Advisory Board |
Luca Pani | - | 2020 | Member of Scientific Advisory Board |
Thomas P. Laughren | - | 2020 | Member of Scientific Advisory Board |
Sanjay Johan Mathew | - | 2020 | Member of Scientific Advisory Board |
Stephen M. Stahl | - | 2020 | Member of Scientific Advisory Board |
Fabiana Fedeli | - | 2023 | Independent Director |
John Glasspool | 59 | 2019 | Independent Director |
Eric Thomas Schmidt | 53 | 2019 | Independent Director |
Paul Kelly | 66 | 2015 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review